AMC Capital IV SCSp has invested EUR 10.0 million in Optimapharm d.d., a leading Clinical Research Organisation in Croatia, marking a strategic move to capitalize on the growing CRO market in Central and Eastern Europe.

Information on the Target

Optimapharm d.d. is a leading Clinical Research Organisation (CRO) founded in 2006 by Gordana Gregurić-Čišak and Igor Čišak. Based in Zagreb, Croatia, the company specializes in providing comprehensive clinical trial management services to its clients. With a commitment to tailoring solutions that meet specific project needs, Optimapharm demonstrates a strong expertise in navigating the complexities of clinical trials across Europe.

Optimapharm holds a significant competitive edge, marked by its unrivaled access to patient populations in the emerging markets of Central, Eastern, and South Eastern Europe. This advantageous position allows the company to effectively conduct clinical trials that benefit both clients and the broader medical research community.

Industry Overview in the Target’s Specific Country

The clinical research industry in Croatia has been experiencing a steady growth trajectory over the past few years. Favorable regulations, combined with a skilled workforce, have made Croatia an attractive destination